XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.3

Earnings per share

12 Months Ended

Jun. 30, 2025

Disclosure [Abstract]

Earnings per share

Note 28. Earnings per share

		2025 A$‘000				2024 A$‘000				2023 A$‘000
Earnings per share for losses from continuing operations
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(20,702	)			(26,778	)			(20,465	)
Loss after income tax attributable to the owners of Kazia Therapeutics Limited			(20,702	)			(26,778	)			(20,465	)
		Number				Number				Number
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share			547,941,171				263,676,313				184,284,350
		Cents				Cents				Cents
Basic and diluted earnings per share			(3.78	)			(10.16	)			(11.23	)

The number of unissued shares under option that have been excluded from the diluted EPS are 50,813,500 (2025), 36,180,000 (2024), and 14,780,000 (2023).

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 33
-IssueDate 2025-01-01
-Section Disclosure
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI
-URIDate 2025-03-27

+ Details

Name:	ifrs-full_DisclosureOfEarningsPerShareExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	dtr-2022:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	kzia_DisclosureAbstract
Namespace Prefix:	kzia_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration